Why Is PDL BioPharma (PDLI) Up 4.6% Since Last Earnings Report?

- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

 

 

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

It has been about a month since the last earnings report for PDL BioPharma (PDLI). Shares have added about 4.6% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is PDL BioPharma due for a pullback? Before we dive into how investors and analysts have reacted as of late, let’s take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

PDL BioPharmaMisses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma reported earnings of 3 cents per share (including the impact of stock-based compensation expense) in the fourth quarter of 2019, missing the Zacks Consensus Estimate of 5 cents. The bottom line was also lower than the year-ago earnings of 10 cents.

The company reported total revenues of a negative $5.8 million in the quarter against the positive $46 million generated in the prior year. The negative revenues were due to a change in the fair value of royalty rights.

PDL announced a plan to dissolve the company by the end of 2020.

Home of Science
Follow me

- Advertisement -

Discover

Sponsor

Latest

Durham robber drinks lager while trapped under shop shutterson June 15, 2023 at 4:42 pm

The intruder drank from a can of lager while he was pinned down in Durham.The intruder drank from a can of lager while he...

Squeaks Media: Innovator of Blockchain Technology

In the summer of 2021, the world will learn about the new blockchain technology that entrepreneur Hitesh (Neel) Patel and his company have created....

Llanharry murders: Who killed Harry and Megan Tooze?on July 23, 2023 at 6:09 am

Married couple Megan and Harry Tooze were found shot dead in their cowshed.Married couple Megan and Harry Tooze were found shot dead in their...

Slavery: Rishi Sunak rejects call to apologise and pay reparationson April 26, 2023 at 1:49 pm

The PM says "no" to reparations, adding "trying to unpick our history is not the right way forward".By Joshua NevettBBC PoliticsPrime Minister Rishi Sunak...

Rangers 3-1 Braga (3-2 agg): Kemar Roofe extra-time winners puts Scots into semi-finalon April 14, 2022 at 9:34 pm

Rangers reach the Europa League semi-final as a blistering performance powered them past 10-man Braga.
Home of Science
Follow me